louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03704181: Colchicine for Patients With Chagas´ Disease( B1 Stage)
Official title: Effect of Colchicine on Inflammation and Myocardial Fibrosis Assessed by Magnetic Resonance Imaging in Patients With Chagas' Heart Disease
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Chagas Disease
Colchicine Resistance
Keywords: fibrosis
Inflammation
Lead sponsor: University of Sao Paulo General Hospital
Sponsor class: OTHER
Collaborators: name: Fundação de Amparo à Pesquisa do Estado de São Paulo
First posted: 2018-10-12
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study evaluate the addition of colchicine in the treatment of patients with Chagas´disease.

Forty patients will receive colchicine while twenty patients will receive placebo

Detailed description: Chagas disease is considered one of the main cause of dilated cardiomyopathy in Latin America. The histopathological characteristics of Chagas' disease are the presence of myocarditis, destruction of heart fibers, and severe myocardial fibrosis. Colchicine had a protective effect on myocardium, indicated by decreased interstitial myocardial fibrosis and attenuated myocardial inflammation. It is an inflammatory cause of cardiomyopathy and myocardial fibrosis is the hallmark of this disease. Colchicine is a drug used in inflammatory diseases, and could also act on myocardial remodeling interfering in the synthesis of collagen

Eligibility criteria: Inclusion Criteria:

* Clinical and serological diagnosis of Chagas´disease ( Stage B1)
* Must be able to swallow tablets

Exclusion Criteria:

* myocardial infarction or coronary artery disease,
* diabetes mellitus,
* valvular disease,
* creatinine clearance \<30 ml / kg / min
* contraindication to perform cardiac magnetic resonance imaging
* use of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers and aldosterone blockers
* previous use of benzonidazole

Primary outcomes:
measure: Effect of colchicine on myocardial inflammation assessed by magnetic resonance imaging
timeFrame: 1 year
measure: Effect of colchicine on myocardial fibrosis assessed by magnetic resonance imaging
timeFrame: 1 year
Secondary outcomes:
measure: Effect of colchicine on inflammatory markers such as interleukin-1, interleukin-6, interleukin-8, interleukin-10
timeFrame: 1 year
measure: Effect of colchicine on inflammatory marker such as TNF-α
timeFrame: 1 year
measure: Effect of colchicine on inflammatory marker such as interferon-gama
timeFrame: 1 year
measure: Effect of colchicine on T Cruzi polymerase chain reaction
timeFrame: 1 year
Other outcomes:
Locations:
city: São Paulo
country: Brazil
facility: Fabio Fernandes
Study officials:
affiliation: Heart Institute, University of São Paulo
name: Fabio Fernandes, Md, PHD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06457581: Effectiveness of Dry Needling Adjuvant to Selective Serotonin Reputake Inhibitors vs TP Injection for Pain Management
Official title: Effectiveness of Dry Needling Adjuvant to Selective Serotonin Reputake Inhibitors Versus Trigger Point Injection for Pain Management in Fibromyalgia
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Pain
Fibromyalgia
Lead sponsor: Superior University
Sponsor class: OTHER
First posted: 2024-06-13
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The principal objective is to contribute valuable insights that hold direct implications for medical practice and patient care, with the potential to influence health policy pertaining to fibromyalgia management.

Detailed description: The study aims to outline distinct patient subgroups manifesting heightened responsiveness to one therapeutic intervention vis-à-vis the other, thereby facilitating the formulation of more personalized and efficacious treatment modalities.

Eligibility criteria: Inclusion Criteria:

* Stable on SSRIs for at least three months (for Group A)
* Age between 18 and 65 years
* Participants suffering from recent cervical pain without any pathology

Exclusion Criteria:

* Presence of any other chronic pain conditions.
* Contraindications to SSRIs or trigger point injections.
* Pregnancy or lactation.
* History of psychiatric disorders other than depression and anxiety

Primary outcomes:
measure: Pittsburgh Sleep Quality Index (PSQI)
timeFrame: 12 Months
measure: Fibromyalgia Impact Questionnaire:
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Chaudary Muhammad Akram Teaching Hospital
state: Punjab
Study officials:
References:
Clinical trial NCT02678481: MR-targeted vs. Random TRUS-guided Prostate Biopsy
Official title: MR-targeted vs. Random TRUS-guided Prostate Biopsy in Patients With High PSA Values and Previous Negative Biopsy Results: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Prostate Cancer
Keywords: multiparametric magnetic resonance imaging
MR-targeted prostate biopsy
saturation TRUS-guided prostate biopsy
Lead sponsor: Fondazione del Piemonte per l'Oncologia
Sponsor class: OTHER
First posted: 2016-02-09
Enrollment: 90
Sex: MALE
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: To compare prostate cancer (PCa) detection rate of magnetic resonance (MR)-targeted biopsy and transrectal ultrasound (TRUS)-guided biopsy in patients with high PSA values and at least one previous negative prostate biopsy. Subjects will be submitted to a multiparametric MR scan of the prostate and subsequently patients with a suspicious MR for PCa presence will be randomized (1:1) into the two study arms.

Detailed description: In men with previously negative prostate biopsy and persistent elevated PSA value, it is unclear which biopsy strategy offers the highest detection rate for significant PCa. The hypothesis of this study is that MR-targeted biopsy improves the detection rates of significant prostate cancers compared with systematic TRUS-guided prostate biopsy.

Men with at least one previously negative TRUS-guided biopsy and persistently elevated PSA values (\> 4 ng/ml) will be submitted to a multiparametric MR imaging examination of the prostate. Subsequently, participants with suspected regions at MR imaging will be randomized (1:1) into the two study arms. In study arm A patients will be submitted to MR-targeted in-bore prostate biopsy based on the multiparametric MR imaging findings. In study arm B patients will be submitted to systematic TRUS-guided prostate biopsy with saturation scheme.

Eligibility criteria: Inclusion Criteria:

* men aged 50-80
* at least one negative TRUS-guided prostate biopsy
* PSA \> 4 ng/ml
* at least one suspected region detected at multiparametric MR imaging
* signed informed consent

Exclusion Criteria:

* known prostate cancer diagnosis
* contraindication against MR imaging or uncooperative patients

Primary outcomes:
measure: Prostate cancer detection rate
timeFrame: within the 3 months after MR imaging
Secondary outcomes:
Other outcomes:
Locations:
city: Candiolo
country: Italy
facility: Fondazione del Piemonte per l'Oncologia - Candiolo Cancer Institute
state: Turin
Study officials:
affiliation: Fondazione del Piemonte per l'Oncologia
name: Daniele Regge, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03561181: Safety Study of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months
Official title: A Single-center, Open, Phase I Clinical Trial to Evaluate Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Dysentery
Dysentery, Bacillary
Lead sponsor: Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Sponsor class: INDUSTRY
First posted: 2018-06-19
Enrollment: 180
Sex: ALL
Minimum age (years): 3
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to evaluate safety of S.flexneriza-S.sonnei Bivalent Conjugate Vaccine in healthy volunteers aged above 3 Months.


Eligibility criteria: Inclusion Criteria:

* 3 months old and above healthy people.
* Subject or legal representative who consent and has signed written informed consent.
* Subject and parent/guardian who is able to comply with all study procedures.
* Subject who did't receive blood products within 30 days ,immune with any live vaccine within 14 days and inactivated vaccine within 7 days before vaccination.
* Axillary temperature ≤37.0 ℃.

Exclusion Criteria:

* Febrile illness (temperature ≥ 38°C) in the 3 days.
* Subject who are allergic to tetanus toxoid.
* Allergic history after vaccination.
* Immunodeficiency diseases patients who administered with immunosuppressive agents.
* In pregnancy or lactation or pregnant women.
* Subject who are suffering from serious chronic diseases, infectious diseases, active infection, cardiovascular disease,liver or kidney disease.
* Subject who have symptoms such as diarrhea, abdominal pain, and pus and bloody stools in the past 3 days.
* History of allergy，eclampsia, epilepsy,brain trauma,encephalopathy and mental disease or family disease.
* Subject who diagnosis of thrombocytopenia or other history of coagulopathy may cause intramuscular contraindication.
* Children with abnormal labor（pregnancy week\<37w,\>42w）,birth weight (\<2500g,\>4000g), asphyxia rescue history,congenital malformations or developmental disorders(Only applicable to 3-5 months old group)
* Blood routine, blood chemistry and urinalysis laboratory collection abnormalities and the severity of grade 2 and above before immunization.
* Subject who plan to participate in or is in any other drug clinical trial.
* Any condition that, in the judgment of investigator, may affect trial assessment.

Primary outcomes:
measure: Occurrence of adverse events during a 30 day follow-up period after each vaccination
timeFrame: 30 day after each vaccination
Secondary outcomes:
Other outcomes:
Locations:
city: Yizhou
country: China
facility: Yizhou Center for Disease Control and Prevention
state: Guangxi
Study officials:
affiliation: Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
name: Du lin, Master
role: STUDY_CHAIR
References:
Clinical trial NCT01743781: Uptake of Comprehensive Eye Examination Trial
Official title: The Impact of Multimedia Education on Uptake of Comprehensive Eye Examination in Rural Southern China:A Randomized, Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Glaucoma
Diabetic Retinopathy
Keywords: comprehensive eye examination
acceptance
glaucoma
diabetic retinopathy
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
Collaborators: name: Orbis
name: The World Diabetes Foundation
First posted: 2012-12-06
Enrollment: 459
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: 1. To evaluate a educational intervention promoting acceptance of comprehensive eye examination in rural Guangdong.
2. To evaluate the impact of acceptance of comprehensive eye examination in rural Guangdong.

Detailed description: A comprehensive eye examination includes visual acuity, slitlamp exam, pupil exam, intraocular pressure, gonioscope lens and 90D lens with slitlamp exam fundus. A number of eye diseases are irreversible at on early stage. Both glaucoma and diabetic retinopathy(DR)are frequently asymptomatic until significant, often-irreversible, damage to the vision has already occurred. It has been estimated that only 10% of persons in India with glaucoma are diagnosed, and the Handan Eye Survey reports that only 10% of persons with diabetes in rural areas of China have received diabetic eye care. In order to deliver effective care for DR and glaucoma in areas with limited resources, education of patients and interventions to promote compliance among patients will both be needed.

Eligibility criteria: Inclusion Criteria:

* age ≥40 years who have never had a comprehensive eye examination

Exclusion Criteria:

* inability to join informed consent

Primary outcomes:
measure: The acceptance rate of comprehensive eye examination in both groups
timeFrame: 1 day
Secondary outcomes:
measure: knowledges of eye disease and attitude of eye examination
timeFrame: 1 day
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: 54 Xianlie Rd
state: Guangdong
Study officials:
affiliation: Sun yat-sen university, Zhongshan Ophthalmic Center
name: Nathan Congdon, MD,MPH
role: PRINCIPAL_INVESTIGATOR
affiliation: Sun Yat-sen University,Zhongshan Ophthalmic Center
name: Mingguang He, MD,PHD
role: PRINCIPAL_INVESTIGATOR
affiliation: Sun Yat-sen University,Zhongshan Ophthalmic Center
name: Aihua Dan, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Dan A, Raubvogel G, Chen T, Ye T, Jin L, Xiao B, Sanchez A, Congdon N. The Impact of Multimedia Education on Uptake of Comprehensive Eye Examinations in Rural China: A Randomized, Controlled Trial. Ophthalmic Epidemiol. 2015;22(4):283-90. doi: 10.3109/09286586.2015.1056812.
Clinical trial NCT00864981: A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting Conditions
Official title: A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting Conditions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Depression
Lead sponsor: Sandoz
Sponsor class: INDUSTRY
First posted: 2009-03-19
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to demonstrate the relative bioequivalence of Bupropion HCI 150 mg SR Tablets under fasting conditions.


Eligibility criteria: Inclusion Criteria:

* No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria:

* Positive test results for HIV or hepatitis B or C.
* Treatment for drug or alcohol dependence.

Primary outcomes:
measure: Bioequivalence according to US FDA timelines
timeFrame: 29 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Novum Pharmaceutical Research Services
name: Shirley A Kennedy, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02747381: The Effect of Vitamin D Supplementation on the Pulmonary Functions of Adult Asthmatic Egyptian Patients
Official title: The Effect of Vitamin D Supplementation on the Pulmonary Functions of Adult Asthmatic Egyptian Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Asthma
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2016-04-21
Enrollment: 82
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study evaluates the effect of vitamin D supplementation in the form of Alfacalcidol on the the pulmonary function of adult asthmatic Egyptian patients

Detailed description: Asthmatic patients are recruited and divided into two groups. One receives Alfacalcidol beside their normal medications while the other acts as a control group receiving the normal asthma medication.

Both groups are followed up for four months.

Eligibility criteria: Inclusion Criteria:

1. Patients diagnosed with asthma
2. Non-smokers

Exclusion Criteria:

1. Liver impairment
2. Kidney impairment
3. Patients receiving digoxin
4. Known hypersensitivity to 1α-hydroxyvitamin D3, vitamin D or any of its analogues and derivatives
5. Hypercalcaemia
6. Hyperphosphatemia
7. Pregnancy and breast-feeding
8. Patients on nutritional supplements with a potential effect on 25(OH)D serum concentrations
9. Had a History of stones in the urinary tract or diseases of calcium or bone metabolism

Primary outcomes:
measure: forced expiratory volume % predicted values
timeFrame: 4 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Faculty of pharmacy, Cairo university
name: Amani Ali
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ali AM, Selim S, Abbassi MM, Sabry NA. Effect of alfacalcidol on the pulmonary function of adult asthmatic patients: A randomized trial. Ann Allergy Asthma Immunol. 2017 May;118(5):557-563. doi: 10.1016/j.anai.2017.02.014. Epub 2017 Apr 1.
Clinical trial NCT04907981: Eye Detection to Identify Novel Coronavirus Infection
Official title: Risk Screening Based on Feature Recognition and Detection of Eye Surface Images of COVID-2019 Patients and Statistical Analysis of High-dimensional Data
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Covid19
Lead sponsor: Wuhan Union Hospital, China
Sponsor class: OTHER
Collaborators: name: Fudan University
name: Hubei Hospital of Traditional Chinese Medicine
name: Fifth Hospital of Shijiazhuang City
First posted: 2021-06-01
Enrollment: 232
Sex: ALL
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Hospital

Brief summary: The eye characteristics of patients with COVID-19 and those without the disease were analyzed, and whether they had the disease or not was judged according to the eye characteristics.

Detailed description: To test the accuracy of a non-invasive eye monitoring that can be widely used for screening in judging patients with novel coronavirus infection.

Eligibility criteria: Inclusion Criteria:

1. All participants were provided with written informed consent at the time of recruitment；
2. Age ≥ 18 and ≤ 75 (informed consent signed by guardian under 18)
3. Meet the diagnostic criteria of novel coronavirus (2019-COVID-19) infection

Exclusion Criteria:

Does not meet any of the inclusion criteria

Primary outcomes:
measure: Collection and analysis of eye characteristics of patients encoding criteria, annotation of ocular feature
timeFrame: 1DAY
Secondary outcomes:
Other outcomes:
Locations:
city: Shijiazhuang
country: China
facility: Shijiazhuang Fifth Hospital
state: Hebei
Study officials:
affiliation: Wuhan Union Hospital, China
name: Lei zhao
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01849081: Evaluating the Efficacy of CPAP Therapy for the Treatment of Fatty Liver
Official title: Evaluating the Efficacy of CPAP Therapy for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Non-alcoholic Fatty Liver Disease
Keywords: Non-alcoholic fatty liver disease
Obstructive sleep apnea
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
Collaborators: name: National Institutes of Health (NIH)
First posted: 2013-05-08
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: We are doing this research study to evaluate whether continuous positive airway pressure (CPAP), a treatment for sleep apnea, will also help treat fatty liver disease. Sleep apnea is a disease where a person has interruptions in their breathing while they are sleep. This can lead to low oxygen levels in the blood. CPAP is a mask that delivers oxygen at high pressure to the lungs to prevent a decrease in blood oxygen levels. CPAP is a known treatment for sleep apnea.


Eligibility criteria: Inclusion Criteria:

* Adults 18 years of age or older with a previous liver biopsy showing NASH and at least grade 2 steatosis
* Obstructive sleep apnea diagnosed by sleep study.

Exclusion Criteria:

* Other causes of chronic liver disease
* cirrhosis
* less than 33% steatosis identified on magnetic resonance spectroscopy (MRS)
* Alcohol use \>2 units per day for women or \>3 units per day for men
* Intolerance to or refusal of CPAP therapy
* overnight desaturation (more than 10% of the sleep time with oxygen desaturation below 85%)
* underlying sever sleepiness (Epworth scale more than 15)
* uncontrolled hypertension
* Severe heart failure (ejection fracture less than 30%)
* cardiac arrhythmias (atrial fibrillation or history of ventricular tachycardia)
* those who are commercial drivers

Primary outcomes:
measure: Steatosis by MRS
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
Study officials:
affiliation: Massachusetts General Hospital
name: Kathleen E Corey, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01598181: Transcranial Direct Current Stimulation (tDCS) as Treatment Method for Pain in Fibromyalgia
Official title: Transcranial Direct Current Stimulation (tDCS) as Treatment Method for Pain in Fibromyalgia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Fibromyalgia
Lead sponsor: University Hospital of North Norway
Sponsor class: OTHER
Collaborators: name: Stiftelsen Helse og Rehabilitering
First posted: 2012-05-15
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate Transcranial Direct Current Stimulation as treatment method for pain in fibromyalgia.

Detailed description: Fibromyalgia (FIM) is a chronic pain condition with high prevalence. Studies involving neuroimaging techniques have identified functional differences in cerebral pain processing in patients with FIM, as compared to healthy controls. This may support that FIM do have a functional CNS component.

Transcranial Direct Current Stimulation (tDCS) is a non-invasive and safe method for inducing changes in cortical excitability. Previous studies showed that anodal stimulation of M1 may change pain perception, possibly by modulating functional anomalies in the FIM brain. The present study has two main goals:

1. To investigate if tDCS may provide FIM patients with symptom relief due to reduction of pain.
2. To investigate tDCS induced functional changes in the brain by using fMRI.

Eligibility criteria: Inclusion Criteria:

* Fibromyalgia (ACR-90 criteria, M79.7 ICD10)
* Mean VAS \> 4 daily 2 weeks prior to study).

Exclusion Criteria:

* Severe mental disease
* CNS disease
* Mental retardation
* Age \< 18

Primary outcomes:
measure: Perceived pain
timeFrame: Change in VAS from baseline up to 49 days.
Secondary outcomes:
measure: Cerebral pain processing
timeFrame: Change from baseline to post treatment. 7 days.
measure: Rating scales (HADS, SCL90, SF36, FIQ)
timeFrame: Change from baseline to post treatment. 30 days post treatment. Up to 65 days.
measure: Perceived pain, natural history
timeFrame: Baseline compared to post-treatment. Up to 65 days
measure: Perceived stress and activation
timeFrame: Change in VAS from baseline to during treatment and after treatment. Up to 49 days.
measure: Perceived stress and activation, natural history
timeFrame: Baseline compared to post-treatment. Up to 65 days
Other outcomes:
Locations:
city: Tromsoe
country: Norway
facility: University Hospital of North Norway
Study officials:
affiliation: University of Tromso
name: Per Aslaksen, ph.d
role: STUDY_CHAIR
References: